Weekly News Recap #Phispers
Chiesi, Arbor in US$ 2 bn gene therapy deal; Lilly to invest over US$ 1 bn in India; FDA okays Boehringer’s rare lung disease drug
In news this week, Italy’s Chiesi Group announced a deal worth up to US$ 2 billion with US-based Arbor Biotechnologies to...
Impressions : 3975
Sarepta inks US$ 11 bn RNA deal with Arrowhead; Roche expands CAR-T arsenal; Novartis buys Kate for US$ 1 bn
The week saw three large deals signed
in promising fields. First, Sarepta Therapeutics signed a US$ 11.4 billion deal
with Ar...
Impressions : 1936
Lilly to acquire IBD drug developer Morphic for US$ 3.2 bn; Pfizer’s R&D chief to step down
This week saw Eli Lilly strike yet another deal as it announced the acquisition of Morphic Holding for about US$ 3.2 billion, t...
Impressions : 1364
Top drugs and pharmaceutical companies of 2018 by revenues
The drug pricing debate continued to dominate news headlines in 2018, and many companies were in the news for lowering drug pri...
Impressions : 35097
Recipharm’s UK facility fails GMP inspection; FDA proposes harmonization of standards for generic drugs
This week, Phispers brings you news on AstraZeneca’s Lynparza that has shown strong benefits for women with ovarian cance...
Impressions : 3521
PhRMA publishes list of US cancer drug pipeline; Biocon-Mylan’s Neulasta biosim bags FDA nod
This week in Phispers, Biocon–Mylan scored a big win by getting the FDA nod for its biosimilar to Amgen’s Neulasta....
Impressions : 2470
- Privacy policy
- Terms and conditions
- Disclaimers
-
- Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.